Login
$YARW
$13.93 +$0.00 (0.0%) After hours

$YARW 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

Enrollment ongoing in the Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without concomitant thyroid eye disease); Phase 2a topline results expected in the se...

14 Sep 2026 8-K: Entry into a Material Definitive Agreement

Introductory. Yarrow Bioscience, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 5,769,231 shares of its common stock, par valu...

10 Sep 2026 8-K: Other Events

Yarrow Bioscience, Inc. (“Yarrow”) is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. Yarrow’s lead product candidate, YB-101 (also known as GenSci098), is a humanize...

30 Jul 2026 8-K: Other Events

On July 29, 2026, Yarrow Bioscience, Inc. (the “Company”) entered into an exchange agreement with a certain existing stockholder (the “Stockholder”), pursuant to which the Stockholder agreed to exchange an aggregate of 133,290 shares of ...

28 Jul 2026 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +8 more

Section 1.1 Registered Office. The registered office of Yarrow Bioscience, Inc., a Delaware corporation (the “Corporation”), shall be fixed in the Amended and Restated Certificate of Incorporation of the Corporation (as the same may be a...

21 Jul 2026 8-K: Regulation FD Disclosure; Other Events

VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience

20 Jul 2026 8-K: Submission of Matters to a Vote of Security Holders

In connection with the Merger, VYNE held a special meeting in lieu of the annual meeting of VYNE stockholders on July 16, 2026 (the “Special Meeting”), at which the Company’s stockholders voted on the proposals set forth below relating t...

14 Jul 2026 8-K: Regulation FD Disclosure

2 Disclaimers The information contained in this presentation has been prepared by Yarrow Bioscience, Inc. and its affiliates (“Yarrow” or t he “Company”) and contains information pertaining to the business and operations of the Company. ...

10 Jul 2026 8-K: Regulation FD Disclosure; Other Events

Aggregate cash dividend of an estimated $16.5 million, or an estimated $0.38 per share

21 May 2026 8-K: Regulation FD Disclosure

1 Bringing life into balance Yarrow Bioscience Overview May 2026

11 Mar 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

As previously disclosed in a Current Report on Form 8-K filed by VYNE Therapeutics Inc. (the “Company”) on September 12, 2025, the Company received a notification from The Nasdaq Stock Market, LLC (“Nasdaq”) that the Company is not in co...

30 Jan 2026 8-K: Entry into a Material Definitive Agreement

This Amendment No. 1 to Agreement and Plan of Merger and reorganization (this “Amendment”) is made as of January 30, 2026, with respect to that certain Agreement and Plan of Merger and Reorganization (as amended to date, the “Merger Agre...

17 Dec 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +3 more

Certificate of Merger, including certificate of incorporation of the Surviving Corporation attached as Exhibit A thereto, incorporated by reference into this Agreement

12 Dec 2025 8-K: Submission of Matters to a Vote of Security Holders

On December 12, 2025, VYNE Therapeutics Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered three proposals, each of which is described in more detail in the Company’s def...

06 Nov 2025 8-K: Results of Operations and Financial Condition

BRIDGEWATER, N.J., November 6, 2025 -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat inflammatory and immune-mediated c...

12 Sep 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On September 11, 2025, VYNE Therapeutics Inc. (the “Company”) received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 p...

14 Aug 2025 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

Implemented cost reductions extend cash runway into first half of 2027

30 Jul 2025 8-K: Results of Operations and Financial Condition; Other Events

Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75

08 May 2025 8-K: Results of Operations and Financial Condition

BRIDGEWATER, N.J., May 8, 2025 -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediate...

06 Mar 2025 8-K: Results of Operations and Financial Condition

BRIDGEWATER, N.J., March 6, 2025 -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-media...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support